Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

Published

Journal Article

Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.

Full Text

Duke Authors

Cited Authors

  • Resnick, SG; Rosenheck, RA; Canive, JM; De Souza, C; Stroup, TS; McEvoy, J; Davis, S; Keefe, RSE; Swartz, M; Lieberman, J

Published Date

  • April 2008

Published In

Volume / Issue

  • 35 / 2

Start / End Page

  • 215 - 225

PubMed ID

  • 18246429

Pubmed Central ID

  • 18246429

Electronic International Standard Serial Number (EISSN)

  • 1556-3308

Digital Object Identifier (DOI)

  • 10.1007/s11414-007-9101-3

Language

  • eng

Conference Location

  • United States